Quanterix Announces Collaboration With Oncogenesis To Develop Cervical Screening Test
Quanterix’ technology to be used in multiplex diagnostic test for cervical disease detection
Lexington, Mass. – Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced a collaboration agreement with OncoGenesis, a molecular protein-based cervical screening company, to develop a quantitative, protein biomarker diagnostic test for cervical health using Quanterix’ next-generation Simoa® Planar Technology. The two companies will jointly complete the development of the test on Quanterix’ forthcoming SP-X™ Imaging and Analysis System and OncoGenesis will commercialize the test in developing countries.
“We are very excited by the potential of this diagnostic test to offer women in the developing world access to an ease-of-use, cost-effective way of monitoring cervical disease,” said Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix. “This represents our first step toward a diagnostic test since recently reestablishing unrestricted rights to our Simoa technology for in vitro diagnostics, and we are very pleased OncoGenesis selected one of our platforms to develop this test.”
Once the CerMark™ Cervical Screening Test is developed and validated, and after OncoGenesis obtains required regulatory approvals, women living in areas with limited medical resources will be able to use OncoGenesis’ iPap™ Home Collection Kit to collect cervical specimens and safely send them to a regional laboratory. The CerMark test is being developed to quantify specific biomarkers reflecting high-risk HPV infection and evidence of cervical disease progression with the goal of eliminating the subjectivity associated with typical cytology. CerMark has the potential to provide clinicians with data to make informed decisions on the risks and status of patient cervical disease at lower costs and with faster turnaround compared to cytology.
“Women in many parts of the world are dying unnecessarily from cervical disease, and we believe the CerMark test has the potential to save many lives through early detection,” said Peter Gombrich, Executive Chairman of OncoGenesis. “Our initial testing with Quanterix’ technology has been very promising and we have a high degree of confidence in our ability to develop a robust diagnostic multiplex assay for cervical disease.”
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.
OncoGenesis is a protein based diagnostics cervical disease company moving its headquarters to Boston, Massachusetts, as part of its collaborative agreement with Quanterix. The company focus along with contracted partners is the final development and marketing of a low cost, high-throughput, multiplex assay detecting cervical disease progression as well as cervical cancer. Its products consist of proprietary cervical collectors including a personal collector, which allows women to collect their own cervical sample. The first system will be a lab based highly sensitive protein detection means looking at multiple patient samples via a multiplexed protein based assay. This lab-based system will prove the value of the markers employed in the assay, which will lead to a Point of Care system in development utilizing the same markers. For additional information, please visit www.oncogenx.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Share this page